![Tirzepatide Tirzepatide](/uploads/etalazecom/products/tirzepatide-68201-b.jpg)
![Tirzepatide Tirzepatide](/uploads/etalazecom/products/tirzepatide-68201-b.jpg)
TIRZEPATIDE 5 MG
Category: Human Peptide Hormone
Package: 2 mL Vial (5 mg/vial)
Form: Powder
Brand: Dragon Pharma
Purpose: For diabetes treatment, weight loss
Tirzepatide is a novel pharmaceutical agent designed to address metabolic disorders, particularly diabetes. It belongs to the class of drugs known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists.
Tirzepatide is composed of a synthetic peptide designed to activate both GIP and GLP-1 receptors, promoting glucose-dependent insulin secretion.
Tirzepatide is typically formulated as a freeze-dried powder, or solution for injection, allowing for subcutaneous administration.
Pharmaceutical group: Incretin mimetics. ATC code: A10BJ03.
Tirzepatide stimulates both GIP and GLP-1 receptors, leading to enhanced insulin secretion, reduced glucagon release, delayed gastric emptying, and increased satiety. These effects collectively contribute to improved glucose control.
Tirzepatide is indicated for the management of type 2 diabetes mellitus in adults, aiming to achieve glycemic control and reduce the risk of cardiovascular events.
Dosage and administration of tirzepatide depend on individual patient needs and response. It is typically administered subcutaneously once a week.
Tirzepatide is not typically cycled like performance-enhancing substances. It is intended for continuous use as part of a diabetes management plan.
Post cycle therapy is not applicable for tirzepatide, as it is a medication for a chronic condition and not used in the context of performance enhancement.
Common side effects may include nausea, vomiting, diarrhea, and injection site reactions. Serious side effects are rare but may include pancreatitis and hypoglycemia.
Tirzepatide is contraindicated in individuals with a history of severe gastrointestinal disease, multiple endocrine neoplasia syndrome type 2, or hypersensitivity to the drug.
There is limited information on overdose, and any suspected overdose should be promptly addressed with medical attention.
Tirzepatide carries warnings for potential risks, including pancreatitis, hypoglycemia, renal impairment, and medullary thyroid carcinoma. Careful patient monitoring is advised.
Tirzepatide may interact with other medications, and healthcare providers should be informed of all drugs taken by the patient.
Freeze-dried powder, in 2 mL vials.
Tirzepatide should be stored according to the manufacturer's instructions, typically in a refrigerator.
Tirzepatide is available for secure and discreet delivery to the USA through authorized supplier - Steroid.biz.
Tirzepatide is a prescription medication and should be used only under the supervision of a qualified healthcare professional.
/
Dragon Pharma
Europe
Please log in to write Tirzepatide review.